| For: | Guo AJ, Deng QY, Dong P, Zhou L, Shi L. Biomarkers associated with immune-related adverse events induced by immune checkpoint inhibitors. World J Clin Oncol 2024; 15(8): 1002-1020 [PMID: 39193157 DOI: 10.5306/wjco.v15.i8.1002] |
|---|---|
| URL: | https://www.wjgnet.com/2218-4333/full/v15/i8/1002.htm |
| Number | Citing Articles |
| 1 |
Jasmine Vohra, Gabriela Barbosa, Lívia Bitencourt Pascoal, Leonardo O. Reis. Advances in Genitourinary Tumor Genomics and Immunotherapy. Genes 2025; 16(6) doi: 10.3390/genes16060667
|
| 2 |
Yuanming Xing, Qian Du, Xulei Dai, Chuanxin Chen, Jingjing Lan, Haisheng You, Siying Chen, Mengmeng Teng. ZBP1-medicated PANoptosis-related signaling contributes to PD-1 inhibitor-associated cardiotoxicity. European Journal of Pharmacology 2026; 1035 doi: 10.1016/j.ejphar.2026.179360
|
| 3 |
Yuanqiang Sun, Ziyang Zhang, Ke Jia, Hong Liu, Furen Zhang. Autoimmune-related adverse events induced by immune checkpoint inhibitors. Current Opinion in Immunology 2025; 94 doi: 10.1016/j.coi.2025.102556
|
| 4 |
Satoka Kinase, Yoshiyuki Nagumo, Bunpei Isoda, Hiromichi Sakurai, Reo Takahashi, Shuhei Suzuki, Akane Yamaguchi, Ryota Yanagihashi, Kozaburo Tanuma, Satoshi Nitta, Masanobu Shiga, Kosuke Kojo, Atsushi Ikeda, Takashi Kawahara, Akio Hoshi, Shuya Kandori, Bryan J. Mathis, Hiroyuki Nishiyama. Blood parameters and whole-blood transcriptomics associated with immune-related adverse events in metastatic renal cell carcinoma during nivolumab plus ipilimumab. Scientific Reports 2026; 16(1) doi: 10.1038/s41598-026-46960-6
|
| 5 |
Yumeng Tian, Yue Yuan, Qian Wei, SiQi Zhang, Xin Nie, Lin Li. From real-world pharmacovigilance data to clinical practice: a geriatric-specific predictive model for immune-related adverse events in lung cancer based on routine clinical indicators. BMC Geriatrics 2026; 26(1) doi: 10.1186/s12877-026-07751-w
|
| 6 |
Allan Stensballe. Toward Precision Health in Autoimmunity and Immune-Related Adverse Events: The Autoantibody Reactome, Spatial Omics, and Multimodal Data Integration. Biomedicines 2026; 14(5) doi: 10.3390/biomedicines14051129
|
| 7 |
Dimitrios Komninos, Emmanouil Psarros, Eva Theochari, George Tsirikos, Fotios Sampsonas, Argyrios Tzouvelekis. When cancer treatment affects the lungs: a clinical overview on pulmonary toxicity induced by new cancer drugs. Expert Review of Respiratory Medicine 2026; 20(7) doi: 10.1080/17476348.2026.2631816
|
| 8 |
Kuan Liang, Ziang Jia, Haiwen Lu, Qianqian Wang, Haihui Huang, Ziling Yan, Yukun Wang, Xia Liu. Inflammatory regulation of PD-L1 protein fate in the tumor microenvironment shapes immune escape and therapeutic targeting. Discover Oncology 2026; 17(1) doi: 10.1007/s12672-026-05544-6
|
| 9 |
Franciszek Kaczmarek, Anna Marcinkowska-Gapińska, Joanna Bartkowiak-Wieczorek, Michał Nowak, Michał Kmiecik, Kinga Brzezińska, Mariusz Dotka, Paweł Brosz, Wojciech Firlej, Paulina Wojtyła-Buciora. Blood-Based Biomarkers as Predictive and Prognostic Factors in Immunotherapy-Treated Patients with Solid Tumors—Currents and Perspectives. Cancers 2025; 17(12) doi: 10.3390/cancers17122001
|
| 10 |
Clara Fernandes, Manas Mahale, Satyam Thakur, Pooja Patel, Rachna Kaul. Role of Biomarkers in Cancer Diagnosis and Therapeutics. 2026; doi: 10.1016/B978-0-443-44041-0.00020-9
|
| 11 |
Marco Agostini, Pietro Traldi, Mahmoud Hamdan. The Search for Predictive Biomarkers in Response to Immune Checkpoint Inhibitors and Associated Adverse Events. Journal of Personalized Medicine 2025; 15(12) doi: 10.3390/jpm15120596
|
| 12 |
Jonathan Thompson, Katie Palen, Smitha Menon, Hui-zi Chen, Tyce Kearl. Pre-treatment polyfunctionality percentage (PFA) of CD8+ T cells is associated with development of immune-related adverse events (irAEs) in patients receiving immune checkpoint inhibitors (ICIs). Neoplasia 2026; 80 doi: 10.1016/j.neo.2026.101353
|
| 13 |
Thaleia-Eleftheria Bousou, Panagiotis Sarantis, Ioanna A. Anastasiou, Eleni-Myrto Trifylli, Dimitris Liapopoulos, Dimitra Korakaki, Evangelos Koustas, Michalis Katsimpoulas, Michalis V. Karamouzis. Biomarkers for the Evaluation of Immunotherapy in Patients with Cholangiocarcinoma. Cancers 2025; 17(3) doi: 10.3390/cancers17030555
|
| 14 |
Anqi Lin, Keyin Zheng, Aimin Jiang, Xufeng Huang, Qi Wang, András Hajdu, Zhengrui Li, Jian Zhang, Peng Luo. The Evolving Landscape of Immunotoxicity: Charting Mechanisms and Future Strategies for Immune Checkpoint Inhibitor Adverse Events. Med Research 2025; 1(3) doi: 10.1002/mdr2.70019
|
| 15 |
Saeed Zivari Lashkajani, Yasaman Sadat Azad, Mohammad Taha Nami, Ali Darzi, Mahla shokouhfar, Sina Naddaf faizabadi, Maryam Diansaei, Komeil Aghazadeh-Habashi, Zahra Azimzadeh Tabrizi, Ahmad Ghorbani Vanan. Neurologic complications of immune checkpoint inhibitors: A comprehensive review. Biomedicine & Pharmacotherapy 2025; 192 doi: 10.1016/j.biopha.2025.118669
|
| 16 |
Penghui Liu, Na Li, Jiwu Guo, Gengyu Tong Zhao, Jizhen Wang, Ziyuan Mou, Jie Mao. Immune checkpoint inhibitor therapy for gastric cancer: current status, therapeutic challenges, and future prospects. Frontiers in Immunology 2026; 17 doi: 10.3389/fimmu.2026.1716934
|
| 17 |
Feilong Tan, Li Zhou, Guijiang Huang, Yanhua Li, Wenjie Yin, Hongying Xia. Analysis of Immune-Related Adverse Events of Pembrolizumab Using FAERS Database. Oncology 2025; 103(12) doi: 10.1159/000543520
|